Revolution Medicines, Inc. (NASDAQ:RVMD) Shares Purchased by Nan Fung Group Holdings Ltd

Nan Fung Group Holdings Ltd lifted its position in shares of Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) by 163.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 19,253 shares of the company's stock after buying an additional 11,953 shares during the quarter. Revolution Medicines makes up 0.7% of Nan Fung Group Holdings Ltd's investment portfolio, making the stock its 28th largest position. Nan Fung Group Holdings Ltd's holdings in Revolution Medicines were worth $842,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of RVMD. IFP Advisors Inc acquired a new stake in Revolution Medicines in the 4th quarter worth about $34,000. Sterling Capital Management LLC grew its holdings in Revolution Medicines by 588.7% in the fourth quarter. Sterling Capital Management LLC now owns 1,956 shares of the company's stock valued at $86,000 after purchasing an additional 1,672 shares during the period. Farther Finance Advisors LLC increased its position in Revolution Medicines by 368.3% during the fourth quarter. Farther Finance Advisors LLC now owns 2,051 shares of the company's stock worth $90,000 after purchasing an additional 1,613 shares during the last quarter. Daiwa Securities Group Inc. raised its stake in Revolution Medicines by 521.8% during the fourth quarter. Daiwa Securities Group Inc. now owns 3,787 shares of the company's stock worth $165,000 after purchasing an additional 3,178 shares during the period. Finally, Avanza Fonder AB acquired a new position in shares of Revolution Medicines in the 4th quarter valued at $173,000. Institutional investors and hedge funds own 94.34% of the company's stock.

Insider Transactions at Revolution Medicines

In other Revolution Medicines news, CFO Jack Anders sold 1,864 shares of Revolution Medicines stock in a transaction on Monday, March 17th. The stock was sold at an average price of $39.04, for a total transaction of $72,770.56. Following the sale, the chief financial officer now owns 115,006 shares of the company's stock, valued at $4,489,834.24. The trade was a 1.59 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Margaret A. Horn sold 3,058 shares of the stock in a transaction on Monday, March 17th. The stock was sold at an average price of $39.04, for a total value of $119,384.32. Following the completion of the transaction, the chief operating officer now directly owns 153,533 shares of the company's stock, valued at approximately $5,993,928.32. The trade was a 1.95 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 16,660 shares of company stock worth $650,406. Company insiders own 8.00% of the company's stock.

Wall Street Analyst Weigh In

RVMD has been the topic of several research analyst reports. HC Wainwright lifted their price objective on Revolution Medicines from $72.00 to $73.00 and gave the company a "buy" rating in a research note on Monday, March 3rd. UBS Group upped their target price on Revolution Medicines from $65.00 to $71.00 and gave the stock a "buy" rating in a research report on Wednesday, January 8th. Wedbush reissued an "outperform" rating and set a $67.00 price target on shares of Revolution Medicines in a research report on Thursday, February 27th. Needham & Company LLC reiterated a "buy" rating and set a $59.00 price objective on shares of Revolution Medicines in a research note on Tuesday, April 8th. Finally, Stifel Nicolaus decreased their target price on shares of Revolution Medicines from $78.00 to $64.00 and set a "buy" rating for the company in a research note on Tuesday, April 1st. Twelve equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has an average rating of "Buy" and an average target price of $66.67.

Revolution Medicines Stock Performance

RVMD stock opened at $36.76 on Friday. Revolution Medicines, Inc. has a 1 year low of $29.17 and a 1 year high of $62.40. The stock has a market capitalization of $6.83 billion, a price-to-earnings ratio of -10.24 and a beta of 1.37. The stock's fifty day moving average is $37.79 and its two-hundred day moving average is $44.42.

Revolution Medicines (NASDAQ:RVMD - Get Free Report) last issued its quarterly earnings data on Wednesday, February 26th. The company reported ($1.12) earnings per share for the quarter, missing the consensus estimate of ($1.01) by ($0.11). As a group, analysts predict that Revolution Medicines, Inc. will post -3.49 EPS for the current fiscal year.

About Revolution Medicines

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.